Hypofractionated RT After Mastectomy Is Noninferior to SOC in Breast Cancer
Hypofractionated postmastectomy radiotherapy was noninferior to standard radiation in patients who underwent a mastectomy.
Cisplatin/70 Gy IMRT Cemented as SOC for Nonsmoking p16+ Oropharyngeal Cancer
Experimental regimens did not cross the threshold to show superiority vs standard cisplatin plus 70 Gy radiation in those with HPV-associated oropharynx cancer.
Fertility Preservation Rates May Increase With Uterine Transposition in Pelvic Cancers
Uterine transposition is a newer tactic in the surgical oncology field to help preserve fertility for patients undergoing pelvic radiation.
IMRT Yields Similar QOL Vs Proton Therapy in Localized Prostate Cancer
Data show no differences in bowel function between treatment arms based on factors including age, disease risk, and fractionation schedule.
Neoadjuvant Therapy Trumps Surgery in NSCLC Debate
The University of Chicago goes against Northwestern Medicine to see who will be crowned the winner in the NSCLC debate.
Exploring the Potential Role of JAK Inhibitors in Multiple Myeloma
James R. Berenson, MD, describes ongoing efforts to evaluate treatment with JAK inhibitors like ruxolitinib among patients with multiple myeloma.
Education on Post-Talquetamab Taste Changes May Help Manage Symptoms
Samantha Shenoy, NP, MSN, emphasized educating patients with multiple myeloma to help prepare them for potential taste alterations after talquetamab.
Dato-DXd: A Path to Potential Approval in NSCLC
Experts discussed the advancements in non–small cell lung cancer treatment and developments in both antibody-drug conjugate–based approaches and targeted therapies.
Neurological AEs Not Significantly Affiliated with Talquetamab Treatment
Samantha Shenoy, NP, MSN, indicated that neurological issues were not prevalent with talquetamab, despite occurrences with other bispecifics antibodies.
Optimizing AE Management Post CAR T-Cell Therapy in Multiple Myeloma
Experts spoke about the best practices for mitigating adverse effects associated with CAR T-cell therapy in relapsed/refractory multiple myeloma.
Determining Administration of BCMA, T-Cell Engagers in R/R Multiple Myeloma
Experts in multiple myeloma discussed optimal dosing strategies for bispecific antibodies for patients with relapsed/refractory multiple myeloma.
FDA Approves Selpercatinib for RET Fusion+ Medullary Thyroid Cancer
The FDA granted traditional approval to selpercatinib for patients with advanced or metastatic medullary thyroid cancer with a RET mutation.
Talquetamab/Daratumumab Shows Durable Responses in R/R Multiple Myeloma
The combination of talquetamab plus daratumumab yields improved patient outcomes in those with relapsed/refractory multiple myeloma.
Talquetamab Combo Yields Enduring Responses in R/R Multiple Myeloma
Combining talquetamab with teclistamab elicits responses even among those with extramedullary disease in the RedirecTT-1 trial.
Taking a Multidisciplinary Approach to Thyroid Cancer Treatment
“We are now able to increase the lifespan in some of these most deadly forms of thyroid cancer solely due to gene profiling and targeted medicine,” said Geoffrey David Young, MD, PhD, FACS.
Managing Oral and Dermatologic Adverse Effects in Multiple Myeloma
Samantha Shenoy, NP, MSN, discussed common oral and dermatologic adverse effects associated with talquetamab in patients with myeloma.
ODAC Votes Against PD-L1 as Efficacy Biomarker in Esophageal Cancers
Eleven votes were cast against the favorability of using anti–PD-1 inhibitors in patients with ESCC and a PD-L1 expression of less than 1.
Calcineurin inhibition rescues alloantigen-specific central memory T cell subsets that promote chronic GVHD
These findings demonstrate the potential risks associated with CNI-based immunosuppression in stem cell transplantation without concurrent strategies to eliminate alloreactive T cells.
A first-in-human phase 1, multicenter, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy for adults with relapsed/refractory acute myeloid leukemia
In a multicenter study, researchers have a phase 1, open-label study of CB-012, a next-generation CRISPR-edited allogeneic anti-CLL-1 CAR-T cell therapy, aimed at treating adults with relapsed/refractory AML.
Daratumumab Regimens Improve Depth, Durability of MRD-Negativity Rates in Newly Diagnosed Multiple Myeloma
Extended follow-up from the CASSIOPEIA trial illustrates the PFS and MRD benefits of daratumumab-based induction/consolidation and maintenance therapy.
ODAC Votes Against PD-L1 as Efficacy Biomarker in Gastric Cancers
Ten votes were cast against PD-L1 as an efficacy biomarker for therapies intended to treat patients with gastric or GEJ adenocarcinoma.
Developers Submit Supplemental NDA for Darolutamide/ADT in mHSPC
Results from the ARANOTE trial support the supplemental new drug application for darolutamide/ADT in metastatic hormone-sensitive prostate cancer.
Subgroup Analysis Data Support Daratumumab Combo PFS Benefit in NDMM
A subgroup analysis from the PERSEUS trial showed sustained PFS benefit in patients with newly diagnosed multiple myeloma receiving D-VRd.
Belantamab Combo Shows Promising Outcomes in Transplant-Eligible NDMM
Responses appear to improve over time in those with transplant-eligible newly diagnosed multiple who receive the belantamab mafodotin-based combination.
Real-world Data Supports Findings from FIGHT-202 in Cholangiocarcinoma
Data from a real-world study further illustrates clinical benefit in patients with cholangiocarcinoma receiving pemigatinib.
Uterine Transposition Aims to Preserve Fertility During Radiation
As the uterus is moved to the anterior abdominal wall, patients now have a chance of preserving their fertility during radiation therapy.
FDA Approves Osimertinib in Advanced EGFR+ NSCLC
Findings from the phase 3 LAURA trial support the approval of osimertinib for advanced EGFR-mutated NSCLC.
Ruxolitinib/Selinexor Combo Is Being Evaluated for Multiple Myeloma
Combination therapy with JAK inhibitors may help improve efficacy outcomes for patients with multiple myeloma.
Phase 3 KEYFORM-007 Misses Primary End Point in MSS mCRC
The fixed-dose combination of favezelimab and pembrolizumab did not show an improvement in overall survival compared with the standard of care in patients with metastatic CRC.
Expert Commentary on the Product Profile of Tisotumab Vedotin in Cervical Cancer
Laura Bucher-Bailey, PharmD, discussed the approval of tisotumab vedotin-tftv for patients with recurrent or metastatic cervical cancer who have had progression after chemotherapy.
